



ORIGINAL ARTICLE

Short Term Omeprazole Use and Markers of Calcium Homeostasis

Afshin Amini¹, Mahmoud Ali Kaykhaei², Zahra Vaezi², Alireza Bakhshipour^{2*}

¹Department of Medicine, St. Luke's Hospital, 232 S Woods Mill Rd, Chesterfield, MO, 63017, USA

²Department of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran

*Corresponding Author: Alireza Bakhshipour, arbakhshipour@yahoo.com

ARTICLE INFO

Article history

Received: Dec 12, 2018

Accepted: Sept 21, 2019

Published: Dec 25, 2019

Volume: 4

Issue: 4

Key words:

Alkaline Phosphatase (ALP),
Omeprazole, Parathyroid Hormone,
Proton Pump Inhibitors (PPIs),
Serum Calcium, Vitamin D (Vit D)
deficiency

ABSTRACT

Introduction: Several studies indicate a higher prevalence of fracture following long term utilization of proton pump inhibitors, among them omeprazole is the most widely used. However, the exact mechanisms lead to this complication are largely unknown. We studied short term effects of omeprazole on some markers of calcium metabolism. **Materials and Methods:** In thirty young adult patients with gastroesophageal reflux, omeprazole was prescribed at 20 mg twice daily for thirty days. Baseline characteristics as well as data after treatment with omeprazole were compared. We also measure important parameters in sixty age and sex match healthy individuals at baseline. **Results:** Mean age of patients was 31.8 year and there was no significant difference regarding age, sex, body mass index, serum calcium, serum alkaline phosphatase and parathyroid hormone between cases and controls. Although, most of the patients were vitamin D deficient (mean = 29.7 nmol/l); compared to controls serum 25 OH Vitamin D was higher ($P= 0.005$) and serum phosphate was lower ($P= 0.001$) in patients. In addition, there was significant increase in alkaline phosphatase ($P=0.01$) and borderline decrease in serum calcium ($P= 0.057$), thirty days after treatment with omeprazole. **Conclusions:** High dose omeprazole after thirty days in the presence of vitamin D deficiency affects bone turnover probably by decreasing calcium absorption.

INTRODUCTION

Omeprazole is the most widely used proton pump inhibitors (PPIs) (1,2). Several lines of evidence indicate that there is higher prevalence of fracture among users of omeprazole (3-7).

A number of mechanisms have been proposed to explain this phenomenon. Although direct effect of omeprazole on bone may be a plausible mechanism (8-11), the most attractive theory is decrease in calcium absorption due to omeprazole induced hypochlorhydria. In this regard, A number of studies showed decreased intestinal calcium absorption (12-16) while others not (17,18). However, the exact mechanisms by which omeprazole affects bone and calcium metabolism remained to be identified.

The aim of present study was to determine effects of omeprazole on markers of calcium homeostasis in young adults treated for gastroesophageal reflux disease.

MATERIALS AND METHODS

In a prospective study thirty young otherwise, healthy adults with diagnosis of gastroesophageal reflux disease (GERD) were enrolled. Baseline clinical and laboratory characteristics were recorded using a structured questionnaire. Exclusion

criteria were: previous treatment with any gastric acid suppressant (e.g. PPIs, H₂ blockers, Antacids), long duration of symptoms, use of any drug that affects bone and calcium metabolism (e.g. calcium, vitamin D (vit D), bisphosphonates, steroids), smoking, pregnancy, previous gastrointestinal (GI) surgery, malabsorption syndromes, cancers and any disorder that may disturb bone or calcium homeostasis e.g. renal disease. Omeprazole was prescribed at 20 mg twice daily on empty stomach. We conducted a positive pill count to ensure compliance. Thirty days after initiation of treatment the clinical and laboratory data were recorded. A control group consists of sixty age and sex matched healthy individuals were included in study. 5 ml blood was obtained at baseline (patients and controls) and thirty days after treatment (patients) by venipuncture. Sera were extracted and freezes at -80°C until further analysis. Height and weight were measured by stadiometer and clinical scale and body mass index was calculated as weight/height². Serum parathyroid hormone (PTH) and 25 OH vit D were measured by Chemiluminescent assay (CLIA) (Diasorin Inc. USA) with intra assay coefficients of variation less than 5%

and 13% respectively. Serum calcium, phosphate, alkaline phosphatase, magnesium and urinary calcium and creatinine were measured using available commercial kits.

Statistical analyses were performed using SPSS version 18 (SPSS Inc., Chicago, Ill). Data were expressed as mean \pm SE for continuous variables and absolute numbers for categorical variables. Student t test and chi squared test were used for comparison of continuous and categorical variables between groups respectively. Paired sample t test and Wilcoxon sign rank test were used to compare variables at baseline and after intervention. $P\leq 0.05$ was set to be considered as significant. The study protocol was approved by medical ethics committee of Zahedan University of Medical Sciences and informed written consent was obtained from all of participants.

RESULTS

Thirty adult individuals with mean age of 31.8 were included in this study. Female to male ratio was 2:1. Adherence to treatment was more than 96% and none of the patients reported significant side effects. Compared to control group mean serum phosphate was higher ($P=0.001$) and mean serum 25 OH vit D was lower ($P=0.005$) in patients (Table 1). 98% of all of subjects were vit D deficient (Serum 25 OH vit D < 50 nmol/l). Clinical and laboratory findings before and one month after treatment with omeprazole are depicted in Table 2. There were no significant changes in body mass index, serum concentrations of PTH, Phosphate, 25 OH vit D and magnesium and urinary calcium/urinary creatinine (Uca/Ucr) before and after intervention. However, serum concentrations of alkaline phosphatase (ALP) were significantly higher after treatment with omeprazole ($P=0.01$). There was also a trend towards decrease in serum calcium after receiving omeprazole ($P=0.057$).

DISCUSSION

Although, there were no significant changes in serum PTH, 25 OH vit D, Magnesium (Mg), Phosphate (P) and Uca/Ucr, we found a significant increase in serum ALP activity and a trend to decreasing serum calcium after one month of treatment with omeprazole which may be due to a decrease in intestinal absorption of calcium. However, due to high prevalence of vit D deficiency in this region consistent with our previous report (19), these results should be interpreted differently. As calcium plays a critical role in metabolic processes, its plasma concentrations should be kept in a narrow range. In the face of vit D deficiency -due to decreased intestinal calcium absorption- a compensatory rise in PTH causes near normalization of calcium albeit in the expense of bone resorption. In this situation omeprazole further impairs intestinal calcium absorption (by inducing hypochlorohydrria), and causes a decrease however non-significant in serum calcium. On the other hand, further increase in parathyroid hormone leads to increase bone turnover which manifested as a significant rising in serum alkaline phosphatase.

In a study by Kocsis et al. treatment with 20 mg omeprazole daily for 2 weeks in children caused no significant changes in bone turnover (20). However, the study was too short to expect significant changes in bone take place. Furthermore, doses of omeprazole were lower and the patients were

heterogeneous.

A number of studies focused on hypochlorohydric effect of omeprazole on intestinal calcium absorption; most of them showed a decrease in calcium absorption (12,13,16). However, these studies were of small sample size and short duration.

Recently, Hansen et al. showed no statistically significant alteration in calcium absorption following 30 days use of omeprazole in postmenopausal women by calculating true fractional calcium absorption (TFCA) using dual isotope study (17). Although, isotope studies designated as standard mode of TFCA the calcium preparation is calcium chloride that is more bioavailable than natural calcium salts in diet. In addition, this study showed increased isotope absorption after treatment with omeprazole which may be due to decrease in absorption of endogenous calcium. Finally, most of these subjects were overweight or obese and it is well known impact of obesity on calcium kinetics (21,22).

In a similar study Wright et al. investigated effects of esomeprazole on calcium absorption in 12 healthy subjects using TFCA (18). This study was of short duration and small sample size compared to our study. Furthermore, there is some evidence that indicates omeprazole may cause not only decreased calcium absorption but also a more generalized malabsorption syndrome (23-27).

Strengths and Weaknesses

Our study has a large sample size of almost young individuals. Duration of study and dosage of omeprazole are also acceptable. In addition, we include vit D status in this study which is the most important marker of calcium absorption. There are a number of limitations in our study too. Lack of measurement of bone resorption markers and high prevalence of vit D deficiency that may affect our results are the most important weaknesses of study.

Table 1

Clinical and Laboratory characteristics of patients versus control

	Patients (N=30) Mean±SE	Controls (N=60) Mean±SE	P
Sex (M/F)	10/20	20/40	1.0
Age (Years)	31.8±1.6	31.4±1.0	0.8
BMI (Kg/m²)	24.3±0.8	24.3±0.6	0.9
Serum Calcium (mmol/l)	2.4±0.02	2.4±0.01	0.5
Serum P (mmol/l)	1.2±0.3	1.3±0.02	0.001
Serum ALP (IU/L)	172.8±9.4	193.7±8.6	0.1
Serum PTH (ng/l)	69.0±4.6	61.6±3.1	0.1
Serum 25 OH Vit D (nmol/l)	29.7±4.5	15.7±0.5	0.005

Abbreviations;

SE: standard error, M/F: male/female, BMI: body mass index, P: Phosphate, ALP: Alkaline Phosphatase, PTH: parathyroid hormone, 25 OH Vit D: 25 OH Vitamin D

Table 2

Clinical and laboratory findings before and thirty days after treatment with omeprazole

	Before intervention (Mean±SE)	After intervention (Mean±SE)	P
BMI (Kg/m²)	24.3±0.88	24.3±0.89	0.8
Serum ALP (IU/L)	172.8±9.4	180.3±10.8	0.01
Serum Ca (mmol/l)	2.4±0.02	2.4±0.01	0.057
Serum P (mmol/l)	1.2±0.3	1.2±0.03	0.3
Serum PTH (ng/l)	69.0±4.6	72.7±5.5	0.4
Serum Mg (mmol/l)	0.8±0.008	0.8±0.01	0.4
Serum 25 OH Vit D (nmol/l)	29.7±4.5	26.4±2.7	0.1
Uca/Ucr (mmol/mmol)	0.08±0.009	0.07±0.007	0.2

Abbreviations;

SE: standard error, BMI: body mass index, P: Phosphate, ALP: Alkaline Phosphatase, PTH: parathyroid hormone, 25 OH Vit D: 25 OH Vitamin D, Ca: Calcium, Mg: Magnesium, Uca/Ucr: urinary calcium/urinary creatinine

CONCLUSION

In conclusion, we showed that following thirty days, omeprazole affects bone and calcium metabolism through decreased intestinal calcium absorption. Further prospective studies with longer durations and more focus on vit D status are suggested.

ACNOWLEDGMENTS (FUNDING SOURCE)

We would like to thank the Deputy Department of Zahedan University of Medical Sciences for the financial support extended for this study.

AUTHOR CONTRIBUTIONS

All authors contributed equally

CONFLICT OF INTERESTS

None.

ETHICAL STANDARDS

Written informed consent was obtained from the patients.

REFERENCES

- Jacobson BC, Ferris TG, Shea TL, Mahlis EM, Lee TH, Wang TC. Who is using chronic acid suppression therapy and why? *Am J Gastroenterol.* 2003;98(1):51-8
- Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: A review of cost-effectiveness and risk in PPI. *Amer J Gastroenterol.* 2009;104:S27-S32
- Roux C, Briot K, Gossec L, Kolta S, Blenk T, Felsenberg D, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. *Calcif Tissue Int.* 2009;84(1):13-9
- Khalili H, Huang ES, Jacobson BC, Camargo CA, Feskanich D, Chan AT. Use of proton pump inhibitors and risk of hip fracture in relation to dietary and lifestyle factors: A prospective cohort study. *BMJ.* 2012;344:e372
- Ngamruengphong S, Leontiadis GI, Radhi S, Dentino A, Nugent K. Proton pump inhibitors and risk of fracture: A systematic review and meta-analysis of observational studies. *Amer J Gastroenterol.* 2011;106(7):1209-18
- Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. *Calcif Tissue Int.* 2006;79(2): 76-83
- Yang YX, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. *J Am Med Assoc.* 2006;296(24):2947-53
- Pytlik M, Cegiela U, Nowinska B, Folwarczna J, Śliwiński L, Kaczmarczyk-Sedlak I, et al. Bone remodeling after administration of proton pump (H⁺/K⁺-ATPase) inhibitors and alendronate in ovariectomized rats. *Acta Pol Pharm - Drug Res.* 2012;69(1):113-20
- Fossmark R, Stunes AK, Petzold C, Waldum HL, Rubert M, Lian AM, et al. Decreased bone mineral density and reduced bone quality in H⁺/K⁺-ATPase beta-subunit deficient mice. *J Cell Biochem.* 2012;113(1):141-7
- Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H⁺, K⁺-ATPase, on bone resorption in humans. *Calcif Tissue Int.* 1993;53(1):21-5
- Hyun JJ, Chun HJ, Keum B, Seo YS, Kim YS, Jeon YT, et al. Effect of omeprazole on the expression of transcription factors in osteoclasts and osteoblasts. *Int J Mol Med.* 2010;26(6):877-83
- O'Connell MB, Madden DM, Murray AM, Heaney RP, Kerzner LJ. Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. *Am J Med.* 2005;118(7):778-81
- Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M, et al. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. *Nephrol Dial Transplant.* 1995;10(8):1376-80
- Graziani G, Badalamenti S, Como G, Gallieni M, Finazzi S, Angelini C, et al. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload: Role of gastric acid secretion. *Nephron.* 2002;36(4):345
- Hardy P, Sechet A, Hottelart C, Oprisiu R, Abighanem O, Said S, et al. Inhibition of gastric secretion by omeprazole and efficiency of calcium carbonate on the control of hyperphosphatemia in patients on chronic hemodialysis. *Artif Organs.* 1998;22(7):569-73
- Milman S, Epstein EJ. Proton pump inhibitor-induced hypocalcemic seizure in a patient with hypoparathyroidism. *Endocr Pract.* 2011;17(1):104-7
- Hansen KE, Jones AN, Lindstrom MJ, Davis LA, Ziegler TE, Penniston KL, et al. Do proton pump inhibitors decrease calcium absorption? *J Bone Miner Res.* 2010;25(12):2786-95
- Wright MJ, Sullivan RR, Gaffney-Stomberg E, Caseria DM, O'Brien KO, Proctor DD, et al. Inhibiting gastric acid production does not affect intestinal calcium absorption in young, healthy individuals: A randomized, crossover, controlled clinical trial. *J Bone Miner Res.* 2010;25(10):2205-11
- Kaykhaei MA, Hashemi M, Narouie B, Shikhzadeh A, Rashidi H, Moulaei N, et al. High prevalence of Vitamin D deficiency in Zahedan, Southeast Iran. *Ann Nutr Metab.* 2011;58(1):37-41
- Kocsis I, Arató A, Bodánszky H, Szönyi L, Szabó A, Tulassay T, et al. Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. *Calcif Tissue Int.* 2002;71(2):129-32
- Shapses SA, Sukumar D, Schneider SH, Schlusell Y, Brolin RE, Taich L. Hormonal and dietary influences on true fractional calcium absorption in women: Role of obesity. *Osteoporos Int.* 2012;23(11):2607-14
- Hultin H, Edfeldt K, Sundbom M, Hellman P. Left-shifted relation between calcium and parathyroid hormone in obesity. *J Clin Endocrinol Metab.* 2010;95(8):3973-81
- Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased Incidence of Small Intestinal Bacterial Overgrowth During Proton Pump Inhibitor Therapy. *Clin Gastroenterol Hepatol.* 2010;8(6):504-8
- Ruscin JM, Lee Page R, Valuck RJ. Vitamin B12 deficiency associated with histamine2-receptor antagonists and a proton-pump inhibitor. *Ann Pharmacother.* 2002;36(5):812-6
- Thongon N, Krishnamra N. Omeprazole decreases magnesium transport across Caco-2 monolayers. *World J Gastroenterol.* 2011;17(12):1574
- Hoorn EJ, van der Hoek J, de Man RA, Kuipers EJ, Bolwerk C, Zietse R. A Case Series of Proton Pump Inhibitor-Induced Hypomagnesemia. *Am J Kidney Dis.* 2010;56(1):112-6
- Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. *Clin Endocrinol (Oxf).* 2008;69(2):338-41